Results 71 to 80 of about 9,143 (202)

Genetic diversity of E6, E7 and the long control region in human papillomavirus type 16 variants in Beijing, China

Biochemistry and Biophysics Reports, 2022
Background: High-risk human papillomavirus type 16 (HPV16) is a risk factor for cervical cancer. The progression from initial infection to cervical cancer has been linked to properties of the viral sequences.
Jiao Wang, Yifan Guo, Hui Wang, Ying Li, Li Zhang, Zhan Wang, Lei Song, Hongtu Liu   +7 more
doaj   +1 more source

Dynamic response of HPV16/anti-HPV16 pairs with unbinding events studied by atomic force microscopy

Biochemistry and Biophysics Reports, 2016
This paper proposes an effective approach to distinguish whether samples include Human Papilloma virus type-16 (HPV16) by Atomic force microscopy (AFM). AFM is an important instrument in nanobiotechnology field. At first we identified the HPV16 by Polymerase chain reaction (PCR) analysis and Western blotting from specimen of the HPV patient (E12) and ...
Lin, Shiming, Hong, Chung-Hung, Sheu, Bor-Ching, Wu, Long-Xin, Huang, Wan-Chen, Huang, Wei-Chih, Guo, Cheng-Yan   +6 more
openaire   +2 more sources

Different Pattern of Treatment Failure After Chemoradiation Between p16+ and p16− Patients Affected by Oropharyngeal Carcinoma

Head &Neck, EarlyView.
ABSTRACT Background Oropharyngeal cancer (OPC) exhibits distinct clinical behaviors according to HPV/p16 status and smoking exposure. While HPV‐positive OPC generally shows superior survival, differences in recurrence patterns remain unclear. Methods A retrospective multicenter analysis of 674 AJCC VII edition Stage III–IVa/b OPC patients treated with ...
Riccardo Gili, Paolo Bossi, Luca Lalli, Lisa Francesca Linda Licitra, Marta Maddalo, Almalina Bacigalupo, Liliana Belgioia, Jon Cacicedo, Nadia Facchinetti, Almudena Garcia Castano, Marc Oliva, Pierluigi Bonomo, Giuseppe Sanguineti, Pierfrancesco Franco, Athanassios Argiris, Amanda Psyrri, Ester Orlandi   +16 more
wiley   +1 more source

HPV16-miRNAs exert oncogenic effects through enhancers in human cervical cancer

Cancer Cell International
Background Cervical cancer is a human papillomavirus (HPV)-related disease. HPV type 16 (HPV16), which is the predominant cause of cervical cancer, can encode miRNAs (HPV16-miRNAs). However, the role of HPV16-miRNAs in the pathogenesis of cervical cancer
Yunuan Wang, Xueying Wang, Yiting Liu, Yuxin He, Xiaoling Duan, Qinmei Li, Yanchun Huang, Guoxiong Xu, Qi Lu   +8 more
doaj   +1 more source

Disease Site‐Specific Outcomes in p16‐Positive Non‐Oropharyngeal Mucosal Head and Neck Cancer

Head &Neck, EarlyView.
ABSTRACT Objectives To report disease‐free survival (DFS) in p16‐positive non‐oropharyngeal head‐and‐neck squamous‐cell carcinoma (HNSCC). Methods Curatively‐treated non‐oropharyngeal HNSCC (2009–2021) were reviewed. DFS was compared among p16‐positive, p16‐negative, and p16‐untested cases for the overall cohort and by disease site.
Revadhi C. Chelvarajah, Lessandra Y. S. Chee, Jie Su, Brian O'Sullivan, Christopher M. K. L. Yao, Enrique Sanz‐Garcia, Stephen M. Smith, Ilan Weinreb, Scott Bratman, B. C. John Cho, Ezra Hahn, Andrew Hope, Ali Hosni, John Kim, Andrew McPartlin, Nauman Malik, Chiaojung Jillian Tsai, John de Almeida, Anna Spreafico, Li Tong, Shao Hui Huang, John N Waldron   +21 more
wiley   +1 more source

Transcription factor c-Rel regulated by E5 affects the whole process after HPV16 infection through miR-133a-modulated feedback loop aim at mir-379-369 cluster

Cancer Cell International, 2022
Background During the development of cervical cancer, HPV infection causes a series of changes in transcription factors and microRNAs. But their relationships with pathogenic processes are not clear.
Juan Zhou, Yongpeng Li, Ke Xu, Yan Rong, Siting Huang, Hailun Wu, Xianlin Yi, Chanzhen Liu   +7 more
doaj   +1 more source

Vaccination of full-length HPV16 E6 or E7 protein inhibits the growth of HPV16 associated tumors

Oncology Reports, 2010
Cervical cancer is the second most common cancer in women worldwide. Human papillomavirus (HPV) is the primary etiologic agent of cervical cancer. Two HPV16 proteins, E6 and E7, are consistently expressed in tumor cells. Most therapeutic vaccines target one or both of these proteins.
Yan-Li, Li, Xu-Hua, Qiu, Chen, Shen, Jian-Ning, Liu, Jing, Zhang   +4 more
openaire   +3 more sources

Health Care Policy Implementation Trial of Primary Human Papillomavirus–Based Cervical Screening in Denmark

International Journal of Cancer, EarlyView.
Uncertainty has persisted over whether human papillomavirus (HPV) testing outperforms high‐quality cytology in real‐world cervical cancer screening programs. To address this, Denmark launched a nationwide trial in 2021, implementing an HPV‐based screening strategy using specialized algorithms integrated with molecular and cytology triage to optimize ...
Jesper Bonde, Jeppe Bennekou Schroll, Birgitte Tønnes Pedersen, Elsebeth Lynge, Marianne Waldstrøm, Petra Hall Viborg, Anna Frandsen, Rikke Holst Andersen, Susanne Nielsen, Doris Schledermann, Bettina Kjær Kristensen, Berit Andersen, on behalf of the National Danish Cervical Cancer Screening Steering Committee   +12 more
wiley   +1 more source

Inhibition of nuclear entry of HPV16 pseudovirus-packaged DNA by an anti-HPV16 L2 neutralizing antibody

Virology, 2010
Rabbit anti-HPV16 L2 serum (anti-P56/75) neutralizes multiple oncogenic human papillomaviruses (HPVs). We inoculated HeLa cells with HPV16 pseudovirus (16PV) and with anti-P56/75-bound 16PV (16PV-Ab). Both 16PV and 16PV-Ab attached equally well to the cell surface.
Ishii, Yoshiyuki, Tanaka, Keiko, Kondo, Kazunari, Takeuchi, Takamasa, Mori, Seiichiro, Kanda, Tadahito   +5 more
openaire   +2 more sources

Clinical Validation of Four Point‐of‐Care High‐Risk HPV Assays, Including Two Reduced‐Valency Assays, for Cervical Cancer Screening in Low‐Resource Settings

International Journal of Cancer, EarlyView.
High‐risk human papillomavirus (hrHPV) testing improves cervical cancer screening by facilitating earlier detection and prevention. In low‐resource settings, however, cost and increased referrals limit its use. At the same time, many new and more affordable assays lack validation.
Neerja Bhatla, MaryLuz Rol, Seema Singhal, Showket Hussain, Anushree Patil, Pranay Tanwar, Shalini Singh, Vikrant M. Bhor, Kiran Munne, Richa Vashishtha, Shachi Vashist, Eric Lucas, Richard Muwonge, Arianis Tatiana Ramírez, Anju Singh, Vikas Khan, Jyoti Rani, Nasera Firdausi, Sandeep Sisodiya, Rutuja Wakchaure, María Alejandra Picconi, Alejandro Calderón, Margo Bell, Annemie De Smet, Alex Vorsters, Gary M. Clifford, Madhavi Chandra, Jitendra Kumar, Partha Basu   +28 more
wiley   +1 more source